证券代码：688273 证券简称：麦澜德 公告编号：2025-036 南京麦澜德医疗科技股份有限公司 关于取消监事会、修订《公司章程》并办理工商变更登 记、修订及新增公司部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召 开第二届董事会第十五次会议，审议通过了《关于取消监事会、修订 <公司章程> 并办理工商变更登记的议案》和《关于修订及新增公司部分治理制度的议案》， 并授权相关人员办理工商登记、备案相关事宜。现将有关情况公告如下： 一、取消监事会的情况说明 为符合对上市公司的规范要求，进一步完善公司治理，根据 2024 年 7 月 1 日 起实施的《中华人民共和国公司法》（以下简称"《公司法》"）《关于新公司 法配套制度规则实施相关过渡期安排》《上市公司章程指引》（以下简称"《章 程指引》"）等相关法律法规、规章及其他规范性文件的规定，公司拟不再设置 监事会与监事，由董事会审计委员会行使监事会职权，《监事会议事规则》等监 ...

南京麦澜德医疗科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年度评估报告 为持续践行"以投资者为本"的上市公司发展理念，推动公司高质量发展和 投资价值提升，维护全体股东利益，基于对公司未来发展前景的信心及公司价值 的认可，南京麦澜德医疗科技股份有限公司（以下简称"公司"或"麦澜德"） 于 2025 年 4 月 24 日发布了《关于 2024 年度"提质增效重回报"行动方案评估 报告暨 2025 年度"提质增效重回报"行动方案》。2025 年上半年，公司根据行 动方案内容，积极开展和落实各项工作。现将 2025 年半年度行动方案执行评估 情况报告如下： （一）"主营业务深耕细作，创新驱动发展"方面 报告期内，公司紧紧围绕发展战略和年度目标，稳步推进各项工作。报告期 末，公司资产总额 152,293.47 万元，归属于上市公司股东的净资产 133,578.70 万元。报告期内，公司实现营业收入 24,122.27 万元，同比增长 5.62%；实现归 属于上市公司股东的净利润 6,392.01 万元，同比下降 11.96%；实现归属于上市 公司股东扣除非经常性损益后的净利润 6,072.30 ...

Core Viewpoint - The company has approved the use of self-raised funds to pay for part of the fundraising project expenses, which will later be replaced with equivalent amounts from the raised funds, ensuring that the normal operation and project construction are not affected [1][4][6]. Fundraising Basic Situation - The company raised a total of RMB 90,975.85 million through its initial public offering, with a net amount of RMB 90,975.85 million after expenses [1][2]. - The funds are stored in a special account for fundraising, and a tripartite supervision agreement has been signed with the sponsor and the bank [2]. Fundraising Investment Project Situation - The total investment for the fundraising projects is RMB 65,000.48 million, with RMB 57,377.94 million planned to be funded from the raised funds and RMB 7,622.54 million from self-raised funds [2]. Reasons for Using Self-Raised Funds - The company needs to use self-raised funds for certain expenses due to operational inefficiencies and regulatory requirements regarding employee salary payments and other miscellaneous expenses [3][4]. - This approach aims to improve the efficiency of fund usage and project implementation [4][6]. Confirmation of Previous Use of Self-Raised Funds - The company has already used self-raised funds amounting to RMB 2,122.47 million for project-related expenses, including salaries and utility fees, which will be replaced by raised funds [3][4]. Impact on Daily Operations - The use of self-raised funds will not affect the normal implementation of fundraising projects and is expected to enhance operational efficiency [4][6]. Review Procedures - The board of directors and the supervisory board have approved the use of self-raised funds, confirming that it aligns with regulatory requirements and does not harm shareholder interests [5][6]. Sponsor's Verification Opinion - The sponsor has verified that the use of self-raised funds for project expenses and subsequent replacement with raised funds is compliant with regulations and does not affect the normal operation of the fundraising projects [6].

或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 按照中国证券监督管理委员会《上市公司募集资金监管规则》、上海证券交 易所《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有 关规定，南京麦澜德医疗科技股份有限公司（以下简称"公司"或"本公司"）董事会 编制了 2025 年半年度（以下简称"报告期内"）募集资金存放与实际使用情况的专 项报告如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账情况 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限公司首次公开发行股票注册的批复》（证监许可〔2022〕1189 号），公司获准 向社会公众公开发行人民币普通股（A 股）2,500 万股，每股面值为人民币 1 元， 每股发行价格为人民币 40.29 元，募集资金总额为人民币 100,725.00 万元，扣除各 项发行费用人民币 9,749.15 万元（不含增值税）后，实际募集资金净额为人民币 行的资金到位情况进行了审验，并出具了天衡验字(2022)00085 号《验资报告》。 公司已对募集资金进行了专户存储，并与保荐机构、专户存储募集资金的相 关银行签 ...

Core Viewpoint - The company plans to increase its estimated daily related party transaction limit for 2025 to RMB 8 million, which is deemed necessary for its normal business operations and complies with fair market principles [1][2][3] Summary by Sections Daily Related Party Transactions - The independent directors of the company believe that the increase in daily related party transactions does not involve unnecessary related transactions and adheres to fair pricing principles [1][2] - The estimated amount for the increased daily related party transactions is RMB 8 million, which is part of the company's normal business activities [1][2] Approval Process - The increase in the estimated daily related party transaction limit has been approved by the company's board of directors and does not require shareholder meeting approval [1][3] - The supervisory board has also confirmed that the increase aligns with the company's operational needs and does not harm the interests of shareholders, especially minority shareholders [2][3] Transaction Details - The main content of the related party transactions includes selling goods to the related party, with all transactions to be formalized through written agreements based on fair market prices [6] - The company has established a good cooperative relationship with the related party, ensuring that the transactions will not adversely affect the company's independence or lead to dependency on the related party [6][7] Financial Impact - The company asserts that the related party transactions will not have a significant adverse impact on its financial condition or operational results, and the main business will not become dependent on these transactions [7]

Core Points - The article outlines the related party transaction management system of Nanjing Mylande Medical Technology Co., Ltd, emphasizing fairness, justice, and transparency in transactions to protect the interests of the company and its shareholders, especially minority investors [2][3][4] - The company defines related party transactions and establishes principles to ensure their legality, necessity, reasonableness, and fairness, while maintaining the company's independence [2][3][4] - The document specifies the scope of related parties and transactions, including various types of transactions such as asset purchases, financial assistance, and guarantees [3][4][5][6] Summary by Sections General Principles - The management system aims to ensure that related party transactions do not harm the interests of the company and its shareholders, particularly minority investors [2] - Related party transactions must adhere to principles of equality, voluntariness, fairness, and transparency [2][3] Definition and Scope of Related Parties - Related parties include individuals or entities that control the company, hold more than 5% of shares, or have close relationships with key management [3][4] - Transactions considered related party transactions include asset sales, investments, and financial guarantees [4][5] Pricing and Management of Related Transactions - Related party transactions should follow pricing principles based on national pricing, market prices, or negotiated prices, with a focus on fairness [6][7] - The financial department is responsible for tracking market price changes and reporting to the board [6] Procedures and Disclosure - Transactions exceeding certain thresholds require approval from independent directors and must be disclosed [8][9] - Related party transactions must be reviewed and disclosed according to specific criteria, including transaction amounts and types [9][10] Special Provisions - The document outlines exceptions for certain transactions that do not require the same level of scrutiny or disclosure [11][12] - Related transactions involving subsidiaries are treated as transactions of the company and must comply with the same management system [12]

Core Points - The implementation details of the cumulative voting system aim to enhance the corporate governance structure of Nanjing Mailland Medical Technology Co., Ltd. and protect the rights of shareholders, especially minority shareholders [1][2] - The cumulative voting system allows shareholders to allocate their voting rights in a flexible manner during the election of two or more directors, ensuring a fairer election process [1][2] - The rules specify that the election of directors must comply with the company's articles of association and relevant laws, and the term of directors elected through this system will not overlap with other terms [2][3] Summary by Sections General Provisions - The cumulative voting system is defined as allowing shareholders to cast their votes based on the total number of shares they hold multiplied by the number of directors to be elected [1] - This system applies when two or more directors are to be elected, and the board must indicate this in the notice for the shareholders' meeting [1][2] Nomination of Director Candidates - Director candidates can be nominated by the board or shareholders holding more than 3% of voting shares, and nominees must provide detailed personal information [2][3] - Nominees must agree to their nomination and commit to fulfilling their duties if elected [3] Election and Voting of Directors - The shareholders' meeting must clearly communicate the cumulative voting method before voting begins, and the board must prepare appropriate ballots [3][4] - Voting rights must be allocated separately for independent and non-independent directors, ensuring no cross-use of votes [4] Election Results - Directors are elected based on the total votes received, with a requirement that the votes exceed half of the total voting rights present at the meeting [5] - If the number of elected directors is less than required, a second round of voting will occur, or a new meeting will be called if necessary [5][6] Miscellaneous Provisions - Any situations not covered by these rules will be resolved according to relevant laws and the company's articles of association [6] - The board is responsible for interpreting and amending these implementation details, which take effect upon approval by the shareholders' meeting [6]

对外担保管理制度 第一条 为规范南京麦澜德医疗科技股份有限公司（以下简称"公司"）对 外担保行为，有效控制担保风险，降低经营风险，保护公司、股东和其他利益 相关者的合法权益，根据《中华人民共和国民法典》《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司监管指引第 8 号——上市公司资金往来、 对外担保的监管要求》等法律、行政法规和规范性文件和《南京麦澜德医疗科 技股份有限公司章程》（以下简称《公司章程》）的有关规定，制定本制度。 第二条 本制度所称对外担保是指公司为他人提供的担保，包括公司对控股 子公司的担保。担保形式包括保证、抵押、质押或其他担保方式。 第三条 未经公司董事会或股东会批准，公司不得对外提供担保。 第四条 本制度适用于公司、全资子公司、控股子公司。公司控股子公司应 在其董事会或股东会做出决议后及时通知公司履行有关信息披露义务。 第二章 对外担保的审批权限 第五条 下述担保事项须经股东会审议批准： （一）单笔担保额超过公司最近一期经审计净资产 10%的担保； 南京麦澜德医疗科技股份有限公司 第一章 总则 （二）公司及公司控股子公司的对外担保总额，超过最近一期经审计净资 产的 50%以后 ...

General Provisions - The purpose of the system is to strengthen the management of shares held by the board of directors and senior management of Nanjing Mylande Medical Technology Co., Ltd. and to clarify relevant procedures based on laws and regulations [1][2] - This system applies to the management of shares held and traded by the company's directors and senior management [2] Prohibited Trading Activities - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or within six months after leaving the company [2][3] - Specific periods during which directors and senior management cannot trade shares include 15 days before the annual and semi-annual report announcements and 5 days before quarterly reports [3] Trading Operations and Restrictions - Directors and senior management must notify the board secretary in writing of their trading plans in advance, and cannot proceed without feedback from the board secretary [4][5] - The maximum number of shares that can be transferred annually by directors and senior management is limited to 25% of their total holdings, with exceptions for certain circumstances [5][6] Reporting and Disclosure Management - Changes in shareholdings must be reported to the board secretary within two trading days and announced on the Shanghai Stock Exchange [10][11] - A reduction plan must be disclosed 15 days prior to the first sale, including details such as the number of shares and the reason for the reduction [9][10] Responsibilities and Penalties - Violations of trading regulations may result in the company recovering profits from illegal trades and reporting the situation to regulatory authorities [11][12] - Serious violations can lead to penalties from the China Securities Regulatory Commission, including market bans for responsible individuals [12][13] Additional Provisions - The system will be implemented upon approval by the company's board of directors and will be interpreted by the board [14][15]

（一）具有注册会计师执业资格； 南京麦澜德医疗科技股份有限公司 独立董事工作制度 第一章 总则 第一条 为了促进南京麦澜德医疗科技股份有限公司（以下简称"公司"或"本 公司"）规范运作，维护公司利益，保障全体股东，特别是中小股东的合法权益， 促进公司规范运作，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《上 市公司独立董事管理办法》（以下简称"《办法》"）等法律、行政法规、规范 性文件和《南京麦澜德医疗科技股份有限公司章程》（以下简称"公司章程"） 的有关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事以外的其他职务，并与本公司及 其主要股东、实际控制人不存在直接或间接的利害关系，或者其他可能妨碍其进 行独立客观判断的关系的董事。 第三条 公司董事会成员中应当有 1/3 以上独立董事，其中至少有一名会计 专业人士。 以会计专业人士身份被提名为独立董事候选人的，应具备较丰富的会计专业 知识和经验，并至少符合下列条件之一： 第二章 独立董事的任职条件及独立性 第七条 担任独立董事必须具备下列基本条件： （二）具有会计、审计或 ...